🔗 Share this article

The first new treatments for gonorrhoea in decades are being viewed as a "significant breakthrough" in the effort against increasingly resistant strains of the bacteria, according to researchers.

An International Public Health Issue

The sexually transmitted infection are escalating around the world, with data suggesting in excess of 82 million infections each year. Especially elevated rates are observed in Africa and nations within the WHO's Western Pacific region, which encompasses Mongolia and China to New Zealand. In England, cases have reached a record high, while figures across Europe in 2023 were three times higher compared to those in 2014.

“The approval of novel therapies for gonorrhoea is an important and timely development in the context of increasing worldwide cases, escalating drug resistance and the highly restricted treatment choices presently on offer.”

Public health authorities are particularly alarmed about the surge in antibiotic-resistant strains. The WHO has listed it as a "critical concern". A tracking program showed that resistance to standard treatments like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

Recent Drugs Secure Clearance

One new antibiotic, also known as a brand name, was cleared by the US FDA in recent days for treating gonorrhoea. This infection can lead to serious health problems, including the inability to conceive. Researchers anticipate that targeted use of this new drug will help slow the spread of drug resistance.

Gepotidacin, originating from the drugmaker GlaxoSmithKline, was also approved in the same week. This treatment, which is employed against urinary tract infections, was shown in trials to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

An Innovative Approach to Creation

Zoliflodacin was the result of a new, not-for-profit approach for antibiotic development. The charitable organization Global Antibiotic Research & Development Partnership worked alongside the drug firm Innoviva to see it through.

“This authorization marks a significant shift in the treatment of multidrug-resistant gonorrhoea, which up to this point has been outpacing our drug pipeline.”

Testing Results and Global Access

According to data published in a prominent scientific publication, the new drug eradicated the vast majority of uncomplicated infections. This places it at an similar efficacy with the current standard treatment, which combines an injection and a pill. The trial included over 900 patients from multiple nations including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its development partnership, GARDP has the authority to make available and distribute the drug in numerous low-income and middle-income countries.

Medical professionals on the front lines have shared positive views. The availability of a single-dose, oral treatment such as this is hailed as a "critical tool" for gonorrhoea control. This is deemed essential to lessen the impact of the disease for people and to stop the proliferation of extremely resistant gonorrhoea globally.